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Abstract
A remarkable aspect of the interaction of Cryptococcus neoformans with mammalian hosts is a consistent increase in capsule
volume. Given that many aspects of the interaction of C. neoformans with macrophages are also observed with amoebae,
we hypothesized that the capsule enlargement phenomenon also had a protozoan parallel. Incubation of C. neoformans
with Acanthamoeba castellanii resulted in C. neoformans capsular enlargement. The phenomenon required contact between
fungal and protozoan cells but did not require amoeba viability. Analysis of amoebae extracts showed that the likely stimuli
for capsule enlargement were protozoan polar lipids. Extracts from macrophages and mammalian serum also triggered
cryptococcal capsular enlargement. C. neoformans capsule enlargement required expression of fungal phospholipase B, but
not phospholipase C. Purified phospholipids, in particular, phosphatidylcholine, and derived molecules triggered capsular
enlargement with the subsequent formation of giant cells. These results implicate phospholipids as a trigger for both C.
neoformans capsule enlargement in vivo and exopolysaccharide production. The observation that the incubation of C.
neoformans with phospholipids led to the formation of giant cells provides the means to generate these enigmatic cells in
vitro. Protozoan- or mammalian-derived polar lipids could represent a danger signal for C. neoformans that triggers capsular
enlargement as a non-specific defense mechanism against potential predatory cells. Hence, phospholipids are the first host-
derived molecules identified to trigger capsular enlargement. The parallels apparent in the capsular response of C.
neoformans to both amoebae and macrophages provide additional support for the notion that certain aspects of
cryptococcal virulence emerged as a consequence of environmental interactions with other microorganisms such as
protists.
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Introduction
Certain environmental microbes exist that have no obvious
need for animal virulence with regards to their survival or
propagation yet these organisms have the ability to cause infection
and disease in a human host. One such organism is the soil fungus
Cryptococcus neoformans, a major pathogen for immunocompromised
individuals, such as those with advanced HIV infection. C.
neoformans has several well-characterized virulence factors [1], and
the most extensively studied virulence factor is its polysaccharide
capsule [2,3]. The capsule is believed to contribute to virulence
through multiple mechanisms as it is both anti-phagocytic and
capable of causing detrimental effects on host immune system
functions [3]. The polysaccharide capsule is also a powerful free
radical sink that protects the fungal cell from oxidants, such as
those produced in the oxidative burst of phagocytic cells [4]. A
remarkable property of the capsule is its ability to undergo
enlargement during infection and this phenomenon is associated
with cryptococcal virulence in the mammalian host [5]. This
enlargement can result in gigantic cells that exceed the size of
macrophages [6,7]. Several factors have been shown to induce this
capsular enlargement, including high CO2, low iron, basic pH,
and mammalian serum [8]. Additionally, capsular enlargement
intensifies protection against both phagocytosis and oxidative
damage [4,9].
C. neoformans is a facultative intracellular pathogen with a unique
replication strategy in macrophages [10,11]. The sophisticated
virulence strategies utilized by C. neoformans in the human host and
the ability of cryptococcal polysaccharide to interfere with the
immune response might suggest that such virulence factors as the
polysaccharide capsule have evolved for evading mammalian
defenses. However, given that C. neoformans does not require a
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of such sophisticated virulence strategies has been a perplexing
problem in the field. Consequently, there has been considerable
interest in characterizing the interactions of C. neoformans with other
soil organisms. Acanthamoeba polyphaga was shown by Bunting et al. to
interact with and ingest cryptococcal cells in classic studies carried out
in the 1970s [12]. In 2001, Steenbergen et al. demonstrated that the
interaction of A. castellanii with C. neoformans was similar to that
observed with macrophages [13]. Recently, this concept has been
extended to the emergence of fungal virulence for insects [14]. Our
group also described the interaction of C. neoformans with three
Parameciumspp., whichwere shown to rapidly ingest and kill the fungus
[15]. These results led to the proposal that the virulence strategies
used by C. neoformans for survival in mammalian hosts had emerged
and developed through environmental interactions, due to the
constant selection by predation [16,17]. In this scenario, cryptococcal
virulence factors are the result of environmental selection and serve
this microbe in mammalian infection by the accidental adaptation to
the host [18]. Additional evidence for this theory comes from the
finding that non-lytic exocytosis from macrophages [19,20] is also
observed with amoeba [21].
Consequently, we hypothesized that the increase in capsule size
may also occur in interactions with amoebae, perhaps as a
mechanism to avoid phagocytosis by those predators. Upon co-
incubation of the amoeba and the fungus, we observed that C.
neoformans responded to the protist by increasing its capsule size.
We have characterized the properties of capsule–inducing
amoebic extracts, including their composition, stability, and effects
on the C. neoformans cells. Additionally, we have observed that the
same response could be elicited by both live and dead
macrophages. These observations led to a search for the signal
sensed by C. neoformans and we report that phospholipids can
trigger both capsule enlargement and giant cell formation.
Results
C. neoformans responds to A. castellanii with capsular
enlargement
Co-incubation of C. neoformans with amoeba elicited an
approximately four-fold increase in the cryptococcal capsular
volume as compared with yeast cells in the absence of amoeba
(Figure 1A and 1C, *p,0.0001). Increase in cryptococcal capsular
volume was similarly observed when C. neoformans cells were
incubated with macrophages as previously observed [22]
(Figure 1A, *p,0.05). Increasing the incubation time to 48 h
produced similar results (data not shown). Co-incubation of C.
neoformans with either dead protozoaor macrophagesalsoresulted in
capsular enlargement, indicating that phagocytic cell viability was
notrequired forthis effect(Figure 1A), althoughboth viableamoeba
and macrophagesinduceda more pronounced effect, twice asmuch
as the capsule increase observed with dead organisms.
Capsular enlargement required cellular contact with
amoebae
We investigated whether the capsule inducing molecule was
diffusible by using 24-well flat-bottom plates where C. neoformans cells
were separated from A. castellanii by 0.4 mm cell culture inserts which
prevented the passage of either organism, but allowed the passage of
small soluble molecules. The C. neoformans cells to be assessed were
placed in PBS below the inserts to allow diffusion to carry any
molecules to these cells. The conditions above the inserts were varied,
a n di n c l u d e dP B Sa l o n ea sac o n t r o l ,A. castellanii to determine if A.
castellanii alone produced a stimulant molecule, and a combination of
A. castellanii and C. neoformans to determine if the combination was
necessary to stimulate production of a small molecule or its chemical
modification. The C. neoformans capsules were measured at 24 and
48 hrs. Measurements included conditions in which only PBS was
placed below the insert for 24 hrs and then C. neoformans was added
for an additional 24 hrs in the event that the reaction required more
time because of the physical separation, but no consistent effects on
capsule enlargement were observed (data not shown). Additionally,
when C. neoformans was placed in A. castellanii cell-free supernatants, no
capsular enlargement was observed, suggesting that A. castellanii does
not secrete a capsule-inducing molecule in solution (data not shown).
We then set up a large volume co-incubation of A. castellanii and C.
neoformans and tested the concentrated supernatant from this
interaction in the activity assay. No activity was found, suggesting
that the active moiety was either not released into the supernatant,
that it remained on the surface of the amoeba, or that it rapidly lost
activity in solution (data not shown).
We considered whether capsular enlargement was a result of
mechanical stimulation by a foreign object such as the amoebae.
This was tested by incubation of fungal cells with 9.2 mm
polystyrene beads. There was no statistical difference between
the capsule volume after incubation with beads and the volume
when C. neoformans was incubated alone in PBS (Figure 1A,
p.0.05), despite documenting that yeast and bead cells could be
found in close proximity to one another (data not shown).
Capsule enlargement occurred at a range of
temperatures
Comparisons of the C. neoformans volume alone in PBS and after
incubation with A. castellanii revealed that the capsule volume was
enlarged at room temperature and above, specifically at 28uC and
37uC (Figure 1B, *p,0.05). The highest ratio of capsule induction
was obtained with incubations at 28uC, which is the optimum
temperature for the growth of the amoeba.
Capsule enlarging compound(s) fractionate to the upper
aqueous phase fraction following lipid extraction
In considering common triggers found in both macrophages and
amoebae, we focused on membrane lipids, given that cell
membranes are highly conserved in eukaryotic evolution. A.
castellanii lipid extraction was performed using the Folch Method
Author Summary
A key event in C. neoformans pathogenesis is capsule
enlargement in mammalian hosts. Historically, this phe-
nomenon was attributed to high CO2 and iron deprivation
but the magnitude of capsular enlargement observed in
vivo cannot be consistently replicated in vitro. This paper
reports that C. neoformans responds to polar lipid extracts
with massive capsule enlargement, with some cells having
dimensions comparable to the giant cells observed in vivo.
Phospholipids are identified in this paper as the inducers
of capsule enlargement. Our work is important because
this is the first host-derived molecule that has been
identified as a stimulus of massive capsule enlargement
thus providing a potential mechanism for the capsular
enlargement observed in vivo. Furthermore, the fact that
the signal is common to both macrophages and amoebae
suggests that the capsule enlargement response to
phospholipids is a mechanism for fungal sensing of
phagocytic cell predators. This provides another example
of a correspondence between a possible environmental
signal and a mechanism of virulence.
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phase, interface, and organic lower phase) which were separated
and incubated individually with C. neoformans serotype D strain
24067. After co-incubation with the extracted fractions for 24 and
48 h, we observed that only the upper polar phase, normally
consideredthe ‘‘non-lipid’’fraction,inducedasignificantincreasein
capsularvolumethat wascomparable tothat observed with intactA.
castellanii (Figure 2A, p.0.05), while no effect was observed with the
lower organic phase or the interface fractions. This effect of the
upperpolarphaseoncapsuleenlargementwasalsoobservedusinga
C. neoformans serotype A strain, H99 (Figure 2B), with a more
pronounced increase compared to controls, despite the lower
absolute numbers compared to the serotype D 24067 strain.
Additionally, when J774.14 macrophage-like cells were subjected to
thesamelipid extractionprotocoland tested inthe activityassay,we
observed parallel results. Upon co-incubation with C. neoformans, the
macrophage upper polar phase was again found to cause capsular
enlargement equivalent to the intact cell (data not shown).
C. neoformans growth in the presence of upper phase
polar extract
Given that capsule enlargement has been linked to stationary
cell growth [8], we investigated the effect of the A. castellanii polar
extract on fungal growth. Using C. neoformans strain 24067, we
compared the growth in PBS and in SDB for 24067 incubated
either alone or with various concentrations of polar extract. In
SDB, the growth curves were found to be identical. In PBS,
growth rates were much slower, however, after 40 h, cells grown
with lipid extract manifested increases in growth rate relative to
PBS, presumably as a result of the fact that the extract could
provide nutrients (data not shown).
Stability of the amoeba extract
We noted that amoeba polar extracts often lost their ability to
induce capsule growth upon storage or additional purification.
Analysis of the stability of the capsule-inducing component over
time revealed a rapid decrease of activity (Figure 2C) such that the
half life of activity decay was calculated to be 1.385 days.
Amoeba extracts induce the production of capsular
polysaccharide and exopolysaccharide
We evaluated the production of both capsular and exopoly-
saccharide following overnight incubation with amoeba extract in
PBS or in minimal medium. Incubation of C. neoformans with the
amoeba upper phase polar extract in PBS resulted in a 2-fold
increase in capsular polysaccharide and a 6-fold increase in
Figure 1. Capsule enlargement can be elicited by mammalian and protozoan cells regardless of viability, but not by mechanical
stimulus. A) The C. neoformans (Cn) cells were incubated alone in PBS, with live and heat-killed A. castellanii (Ac), live and heat-killed J774.14
macrophage-like cells (Mac), and polystyrene beads. Live amoebae and macrophages were more effective than heat-killed cells in triggering capsular
enlargement. In contrast, there was no enlargement in the presence of the polystyrene beads, when compared to incubation in PBS alone. Each assay
was performed independently on 3 separate days and the numbers shown represent the average of a minimum of 50 C. neoformans cells. B) Capsule
enlargement activity of A. castellanii extracts as a function of temperature. Activity assays were done at 4uC, room temperature (RT), 28uC, and 37uC.
This experiment was done two times on separate days and each condition represents a minimum of 50 cells. C) Representative C. neoformans cells
suspended in India ink showing enlargement of the polysaccharide capsule after incubation with A. castellani (40x). (*) indicates P,0.001 for capsule
enlargement for each condition when compared to control incubation alone in PBS.
doi:10.1371/journal.ppat.1002047.g001
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(Figure 3). When C. neoformans was incubated in minimum medium
containing high glucose concentrations, no difference was
observed for either capsular and exopolysaccharide (p.0.05)
production, whether incubated with amoeba extract or alone in
the medium.
Requirement for phospholipase B
Since the capsule enlargement phenomenon required contact
between C. neoformans and amoeba cells, we considered whether
the release of polar lipids from amoeba membranes could be a step
in amoeba-mediated capsular enlargement and thus evaluated the
requirement for fungal phospholipase in this process. Phospholi-
pase B (PLB) can release both sn-1 and sn-2 fatty acids from
phospholipids [24]. C. neoformans produces extracellular PLB and
both PLB-deficient (plb1) and reconstituted (plb1
REC1) strains have
been generated on an H99 background [24]. Both the parental
and the reconstituted strains exhibited the same increase in capsule
volume when incubated with either intact A. castellanii cells or with
the upper phase fraction, but not when incubated with PBS
(Figure 4A, *p,0.05). However, the plb1 mutant strain was unable
to increase the capsular volume under any of these conditions,
indicating a necessity for PLB production.
The necessity for PLB activity led us to investigate whether
other phospholipases may also play a role in the interaction
between the two organisms. The C. neoformans strain 24067, as well
as the parental (H99), the phospholipase C mutant (A ¨isc1), and the
reconstituted (Disc1
REC) strains were tested in the activity assays
with A. castellanii. The C. neoformans phospholipase C mutant strain
Figure 2. Polar fractions from A. castellanii extracts induce C. neoformans capsule enlargement. A) C. neoformans strain 24067 (Cn) was
incubated alone, with intact A. castellanii (Ac), and with the three fractions (upper, interface, and lower) that resulted from lipid extraction of A.
castellanii. The statistically significant increase in capsule volume was only observed with intact amoeba and with the upper phase polar fraction.
Each condition represents a minimum of 50 C. neoformans cells and experiments were done in triplicate. P,0.05. B) C. neoformans strain H99 (Cn) was
incubated in the same manner as 24067, with the same conditions as stated above. The effects for strain 24067 were proportionately greater than for
strain H99. C) Capsule-inducing activity of A. castellanii extracts declines as a function of time. The half-life of activity decay at room temperature was
1.385 d.
doi:10.1371/journal.ppat.1002047.g002
Figure 3. Polar fractions from A. castellanii extracts (AE) induce
C. neoformans strain H99 exopolysaccharide release. This effect
was apparent only when the experiment was carried out in PBS and no
effect was observed when the yeast cells were suspended in minimal
medium (MM), possibly due to glucose repression.
doi:10.1371/journal.ppat.1002047.g003
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incubation with A. castellanii (data not shown).
Serum upper phase lipid extract elicited enlargement in
wild type and plb1 strains
The C. neoformans capsule can be enlarged by incubation in 10%
fetal calf serum (FCS), as described [22]. Consequently, we
investigated whether the capsule-inducing properties of serum
were also due to polar lipids and whether the effect was also PLB-
dependent. Using the same extraction protocol that was used with
A. castellanii, FCS was separated into upper phase, interface, and
lower phase fractions. C. neoformans strains H99, plb1, and plb1
REC1
were tested in activity assays where they were each incubated with
the FCS fractions (Figure 4B). Similar to the results with amoebae,
the FCS capsule-inducing activity was also found in the upper
polar fraction (p,0.05). However, unlike the A. castellanii polar
extract, the FCS polar lipid fraction induced enlargement of the
plb1 capsule, suggesting that for serum-derived polar lipids, there is
no PLB requirement for capsular enlargement.
Effect of heat, glucanase, and protease on extract activity
Both heat and glucanase treatments were found not to affect the
ability of the extract to trigger capsule enlargement (Figure 5A,
p.0.05). However, when the fractions were treated with Proteinase
K and heat, we observed a dramatic 39% increase in the capsule
induction activity when compared to the untreated extract,
suggesting that the active compound may be complexed with a
protein in solution and that its cleavage helps to release the active
compound. The fraction treated with Proteinase K and heat was
subsequently run on a silica TLC plate with a mobile phase of a
65:25:4 ratio of methanol:chloroform:water (Figure 5B). A new
band appeared, with a higher Rf, most likely consisting of free lipids
released after proteinase digestion. We performed a new fraction-
ation using the Folch method following the Proteinase K digestion.
Newupperandlowerphasesincubatedovernightorfor48hwithC.
neoformans showed different results. Activity was fractionated to the
lower phase, which induced capsule enlargement compared to PBS,
with similar levels to treatment with Proteinase K without
fractionation, after both overnight (Figure 5C, *p,0.05) and 48 h
(Figure 5D, *p,0.05) incubations. Interestingly, at both time-points
evaluated, the new upper phase material obtained after fraction-
ation of the Proteinase K digestion resulted in an increase in cell
body volume when compared to PBS.
Purified phospholipids and their polar heads induced
capsule enlargement
The requirement of PLB for capsular enlargement combined
with the new band observed in the polar extract TLC after
Proteinase K treatment suggested that the enlargement activity
was due to a type of phospholipid or phospholipid-derived
molecule from the A. castellanii extracts. Thus, we tested the ability
of a few purified commercially available lipids and lipid-derived
molecules to trigger capsule enlargement.
One of those molecules was phosphatidylcholine (PC), a major
component of amoeba cell membranes. We observed that PC was
able to induce a dose-dependent capsule enlargement in two
different strains of C. neoformans comparable to the one obtained in
the co-incubation experiments (Figure 6A and 6B; Figure S1B).
The average increase varied from 2- to 8-fold (p,0.001)
depending on the conditions of the experiment, with larger
increases when the cells were incubated in MM instead of PBS and
for at least 48 hours. In addition to PC we also tested phosphatidic
acid (PA), phosphatidylethanolamine (PE), phosphatidylglycerol
(PG), phosphatidylinositol (PI), phosphatidylserine (PS) and
lysophosphatidylcholine (LC) (Figure S1B). All the compounds
with the exception of PG and PS produced significant enlargement
of the C. neoformans capsule, however the effects were highest in the
presence of either PC or LC.
Figure 4. Phospholipase B mutants respond to serum components with an increase in capsule size but not to A. castellanii. A) C.
neoformans strains H99, plb1, and plb1
REC1 were used in an activity assay with intact A. castellanii and the upper phase polar fraction. The wild type
and reconstituted strains showed significant increases in capsule volume in the presence of the intact organism and the polar lipid fraction. The plb1
mutant, however, did not show a statistically significant increase in either condition. The numbers shown represent the average of a minimum of 50
C. neoformans cells. The experiment was done independently on 3 separate days and the results were reproducible. B) The Fetal Calf Serum (FCS)
upper phase fraction elicits capsular enlargement, but is not dependent on PLB. FCS was subjected to lipid extraction and separated into fractions.
The fractions were tested in the activity assay with the C. neoformans strains H99, plb1, and plb1
REC1. The active component separated into the polar
fraction, similar to results seen with intact A. castellanii; however, the effect was not dependent on PLB activity as the enlargement of the capsule was
observed in the PLB-deficient strain. (*) indicates P,0.05 for capsule enlargement for each condition when compared to control incubation alone in
PBS for each strain.
doi:10.1371/journal.ppat.1002047.g004
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polar extract treated with or without Proteinase K, demonstrated
the presence of phospholipids. However, phospholipid concentra-
tion was very low when compared to the amount detected in the
untreated non-polar samples by mass spectrometry (data not
shown), therefore precluding molecular identification.
C. neoformans PLB activity has been linked to the generation of
arachidonic acid from fungal phospholipids and to the subsequent
production of eicosanoids, including prostaglandins [25]. Thus, we
hypothesized that arachidonic acid or one of its products could be
responsible for the capsular enlargement, but none of the
compounds tested promoted capsule growth (Table S1).
In addition, we considered that the effect on the C. neoformans
capsule could be caused by the polar head group of the
phospholipids, which also can be derived from PLB activity. It
has previously been shown that GPC is the only degradation
product of PC upon treatment with C. neoformans supernatants
containing PLB activity [26]. Thus, two commercially available
polar head groups, GPE and GPC, were tested with C. neoformans
strains 24067 and H99 in the activity assay (Figure 6A and 6B,
respectively). We observed that both molecules were able to induce
capsule enlargement with differences in their effect dependent on
the C. neoformans strain used (Figure 6A and 6B). After 24 hours of
treatment, 10 mM of GPC was able to induce an average 2-fold
increase in the capsule volume of 24067 and H99 cells (data not
shown) reaching a 5-fold increase in the first strain after 48 hours
of treatment. GPE produced an average 2-fold increase with both
strains, however, was slightly but significantly more active with
H99 cells. Additionally, GPE and GPC were able to induce
capsule enlargement in the PLB-deficient strain comparable to the
enlargement previously observed in the presence of amoeba and
polar extracts (Figure 6C). In this case, GPE was also shown to be
more active against the plb1 mutant than GPC and was also able to
induce the presence of giant-like cells in the mutant cultures. As
observed with the polar extracts, both GPC and GPE were also
shown to lose their activity very rapidly when in solution. We
tested concentrations of GPC and GPE up to 1 mM, however,
concentrations higher than 10 uM did not result in further
Figure 5. Capsular enlargement in response to different extracts. A) Activity of upper phase amoebae extracts (AE) on C. neoformans strain
H99 after extract treatment with heat, Proteinase K (Ptn K), and glucanases. Neither heat nor glucanase treatments had a significant effect on capsule
enlargement activity. In contrast, Proteinase K + heat treatment elicited cells with larger capsule volumes. This experiment was done two times on
separate days and the results were reproducible. The numbers shown represent the average of a minimum of 50 C. neoformans cells. B) Thin liquid
chromatography shows an increase in the mobility of the phospholipid bands upon treatment of amoebae extracts with Proteinase K, and
fractionation of the free lipid compounds to the lower phase fraction. Lane 1: Phospholipid markers: (PE) phosphatidylethanolamine; (PS)
phosphatidylserine; (PI) phosphatidylinositol; and (PC) phosphatidylcholine; Lane 2: Untreated extracts; Lane 3: Untreated extract + Proteinase K
(before treatment); Lane 4: Proteinase K-treated extract; Lane 5: Lower phase fraction after treatment with Proteinase K; Lane 6: Upper phase fraction
after treatment with Proteinase K. C) and D) Demonstration that the active substance in the amoeba extract (AE) shifts from the upper phase to the
lower phase after digestion with Proteinase K (Ptn K). Panels C and D show results from overnight and 48 h, respectively. Chloroform extraction of the
upper phase after Proteinase K digestion (Cn + AE upper phase) enhances the activity of the upper phase to promote cell body size increase, while
the capsule inducing substance transfers to the lower phase (Cn + AE lower phase). (*) indicates P,0.05 for capsule enlargement for each condition
when compared to control incubation in PBS. In Panel C, the (**) indicates P,0.05 for a decrease in capsule relative to incubation in PBS, while in
Panel D (**), indicates P,0.05 for a decrease in cell body volume relative to incubation in PBS.
doi:10.1371/journal.ppat.1002047.g005
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PLoS Pathogens | www.plospathogens.org 6 May 2011 | Volume 7 | Issue 5 | e1002047Figure 6. Capsule enlargement was elicited by glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE), and
phosphatidylcholine (PC). Activity assays were performed to test the effects of GPC, GPE, or PC on the capsule of C. neoformans. A) H99 and
B) 24067 fungal cells were incubated alone in minimal medium (MM), or with 10 mM of GPC or GPE or 5 mM of PC for 48 hours. Each assay represents
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incubation of plb1 mutant cells with intact phospholipids, such as
PC, was not able to induce capsule enlargement, thus supporting
the necessity of the phospholipase B activity in this process (data
not shown).
C. neoformans PLB contains three enzyme activities in one
protein, phospholipase B (PLB), lysophospholipase (LPL) and
lysophospholipase transacylase (LPTA). These activities have been
found to be either secreted or cell associated (either membrane
bound or in the cytosol) [27]. PLB removes both acyl chains from
phospholipids; LPL removes the single acyl chain from lysopho-
spholipids; and LPTA adds an acyl chain to lysophospholipids to
produce phospholipids. To further evaluate the role of PLB in the
capsule enlargement, we tested the effects of three phospholipase
inhibitors (as described [27]) on the capsule enlargement induced
by PC. The first inhibitor was alexidine dihydrochloride
(compound AX) which primarily inhibits secreted PLB activity
at the tested concentration. Another inhibitor was dioctadecyldi-
methylammonium bromide (compound O) which acts mainly on
secretory and cytosolic LPL and LPTA and on cell-associated
PLB. The third inhibitor was palmitoyl carnitine (compound
PAC), which has been found to be a potent inhibitor of PLB
activity at 0.5 mM while affecting LPL and LPTA activities by
only by 35% [28]. We found that compound AX did not affect the
capsule enlargement induced by PC, however both compound O
and compound PAC, which target cell-associated PLB and
secreted and cell associated LPL and LPTA activities, abolished
the capsule enlargement (Figure S3). These results further support
the role of phospholipase B in the capsule enlargement and suggest
that the PLB activity involved in the process is possibly cell-
associated.
Prolonged incubation times resulted in induction of
giant cells
Incubations of C. neoformans yeast with A. castellanii, macrophag-
es, and their respective extracts were evaluated in longer
incubation periods for the induction of cell gigantism. At days 2,
4, and 6, co-incubation with amoeba, macrophages, and the
extracts all induced larger capsule volumes when compared to
incubation in PBS or minimum medium alone (Figure 7A,
p,0.05). After 8 days, we observed an increase in the cell body
volume of these cells and a concurrent reduction of relative
capsular volume, but the overall volume of the C. neoformans yeast
did not display a statistically significant difference. Cells incubated
with amoeba extract and with the intact amoeba cell have a
distinct pattern, with a double-layered capsule and two regions of
different density. These cells had diameters ranging from 15 to
20 mm, approximately the size of giant cells previously described
as forming in vivo [7,22] (Figure 7B). Analysis by indirect
immunoflourescence of capsule-induced C. neoformans cells after 6
days revealed stronger binding than the capsules of C. neoformans
cells in PBS, consistent with the capsule enlargement phenomenon
previously described (Figure 7C). Additionally, India ink staining
and immunofluorescence of C. neoformans cells exposed to PC
a minimum of 50 C. neoformans cells. C) H99, plb1,1 and plb1
REC1 cells were incubated either alone in MM or with 10 mM of GPC or GPE or 5 mM of PC
for 48 hours. The numbers shown represents the average of a minimum of 50 C. neoformans cells. (*) indicates P,0.01 for capsule enlargement for
each condition when compared to control incubation alone in MM.
doi:10.1371/journal.ppat.1002047.g006
Figure 7. C. neoformans capsule and cell size growth in response to A. castellani (Ac), macrophages (Mac), and their upper phase
extracts as a function of time. A) Initial effects involve capsule enlargement but continued incubation results in cells with giant cell bodies.
B) Uvitex 2B preparations demonstrate an increased double-layered capsule of C. neoformans over time when co-incubated with A. castellanii cells
and extracts. An increased cell body size, along with a decreased capsule size, was observed after an 8 day incubation period. C) Immunofluorescence
demonstrates that C. neoformans cells are more intensely labeled with capsular antibodies following treatment with A. castellanii cells and extracts.
Scale bars =10 mm.
doi:10.1371/journal.ppat.1002047.g007
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were even larger than those observed after extended incubation
with A. castellanii, macrophages, and their respective extracts
(Figure 8A, 8B, and 8C). Those cells did not constitute the
majority of the cells, but were notably larger than untreated cells
(Insets in Figure 8A and in 8B and Figure 8D). The whole cells
averaged from 20 to 30 mm and both cell body and capsule were
significantly enlarged and their relative abundance appeared to
increase after longer incubation periods (Figure 8C and 8D).
Discussion
C. neoformans capsular enlargement is a phenomenon that has
frequently been associated with its virulence in mammals [5].
Numerous signals are known to trigger capsule enlargement
including CO2 [29], serum [8], iron deprivation [30], pH, and
certain growth conditions [22]. The fact that chemically diverse
signals trigger capsule enlargement suggests that this phenomenon
may be a non-specific defense against fungal-perceived stress,
threats, and danger. When murine lungs are inoculated with C.
neoformans, capsular enlargement proceeds rapidly. The phenom-
enon, in its extreme and combined with cellular growth, can also
result in the formation of gigantic cells [31]. However, since the
primary ecologic niches of C. neoformans are soils and trees, and
animal infection may be a relatively rare event involving only a
minute fraction of the cryptococcal fungal mass on the Earth, it is
unlikely that capsular enlargement evolved for the specific purpose
of defense in animal hosts. Given that soil amoebae have been
reported to be major predators of C. neoformans in that niche [32],
we investigated whether interactions with protozoa also induced
capsular enlargement.
Incubation of C. neoformans with A. castellanii resulted in capsular
enlargement. The effect required contact between the fungal and
protozoan cells but did not require amoebae viability. Since the
capsule protects C. neoformans against amoebae ingestion, and since
the diameter of the capsule correlates inversely with the efficiency
of phagocytosis [9,21], capsular enlargement is a likely defense
mechanism against phagocytic predators. The absence of a
capsular enlargement response when cryptococci are incubated
with beads implies that the stimulus is more than merely
mechanical and that fungal cells discriminate between inert
spheres and cells.
Since both live and dead amoebae triggered capsular enlarge-
ment and since protozoan cells represented a very different trigger
than previously reported stimuli, we investigated the nature of the
responsible component by fractionating amoebae cells and testing
these fractions for their ability to elicit capsule growth. One of the
approaches was to submit A. castellanii cells to lipid extraction. The
upper polar phase, normally called the non-lipid fraction, had
comparable efficacy to intact amoeba cells in promoting capsular
enlargement. In contrast, neither interface nor the lower phase
lipid extract fractions demonstrated any capsule enlargement
activity. Concurrently, due to the requirement for cellular contact,
we investigated the requirement for fungal phospholipase in
Figure 8. C. neoformans cell gigantism following treatment with phosphatidylcholine (PC). A) Deconvolved immunofluorescence of H99
cells treated with 5 mM PC for 48 hours and labeled with Uvitex 2B (blue) and DTAF-18B7 (green). Inset represents untreated cells under the same
magnification. B) Differential interference contrast of Panel A. C) India ink preparation of H99 cells treated with 5 mM PC for 96 hours. (D) India ink
preparation of untreated H99 cells at the same magnification. Scale bars =5 mm.
doi:10.1371/journal.ppat.1002047.g008
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not phospholipase C, was required for C. neoformans to respond to
amoebae with capsular enlargement.
Combined, these two results were conflicting since the
partitioning to the upper phase during lipid extraction suggested
that the enlargement activity was not due to a lipid molecule, given
that most of the lipids are normally found in the lower organic
phase. Additionally, the requirement for phospholipase B
suggested that the molecule was a phospholipid or at least a
phospholipid degradation product. The treatment with Proteinase
K and the subsequent TLC analysis gave us a possible explanation
for this potential inconsistency. Instead of abolishing the activity,
as would be expected if the activity was due to a polypeptide chain,
the treatment actually increased the extract activity and produced
a new band in the TLC that was compatible with the release of a
phospholipid. In the case of lipids that are covalently associated to
proteins or carbohydrates, they could be carried to the non-lipid
extract during phase partitioning [33]. Thus, our hypothesis is that
the phospholipids responsible for the enlargement activity are
strongly associated with a polypeptide and this association results
in their partitioning to the upper polar fraction during the
extraction. As expected, the activity was transferred to the lower
phase upon Proteinase K digestion and new fractionation,
supporting the hypothesis that free lipids are released. The
treatment with Proteinase K disrupts this interaction, further
building upon the activity of phospholipase B. Additional support
for this observation comes from the fact that, even in the absence
of strong interactions with other molecules, some phospholipids
and other highly polar lipids, such as gangliosides, partition into
the upper phase [34]. Furthermore, mass spectrometry of both
intact crude amoeba polar extracts and those treated with
Proteinase K indeed revealed the presence of different classes of
phospholipids in our samples but their identity could not be
established due to small quantities. Given that phospholipases are
known to damage membranes, we interpreted this result as
indicating that fungal phospholipase B catalyzed the release from
the membrane of lipids and/or lipid fractions that are subse-
quently sensed by the fungal cells. Phospholipase B is known to be
a virulence factor for C. neoformans, but the dependence of capsule
enlargement on this activity implies a potential new role in
cryptococcal biology.
Incubation with amoeba fractions also altered the production of
both capsular and exopolysaccharides. We measured an approx-
imately two-fold increase in the capsular polysaccharide and a six-
fold increase in the exopolysaccharide production in the presence
of amoeba lipid extracts. Given the structural differences in the
capsular and exopolysaccharide fractions, the quantitative differ-
ences in production are consistent with the notion that these
compounds have independent pathways of production and/or
secretion [35].
The observations that protozoan phospholipids triggered
capsular enlargement prompted us to investigate whether
mammalian lipids had the same effect. The polar fractions
extracted from macrophages and serum were also shown to trigger
capsular enlargement. An interesting difference between the effects
observed with amoebae and with serum was the absence of a
phospholipase B requirement in the capsular enlargement
response to serum-derived polar lipids. This observation suggests
that serum lipids are responsible, at least in part, for the ability of
serum to trigger capsule growth. However, serum also contains
iron binding proteins that could conceivably indirectly trigger
capsule growth through iron limitation [30].
We then attempted to identify the specific compound
responsible for the capsular enlargement. Our first approach was
to further fractionate the upper phase from the lipid extraction
using a variety of techniques. However, activity was inevitably lost
with progressive fractionation. Size exclusion and reverse phase
chromatography purification of the polar fractions revealed
activity in at least two fractions but mass spectrometry analysis
of the most active fractions was not revealing (unpublished data).
This suggested that the compound was not stable and/or that the
effect required more than one molecule. Indirect evidence for the
instability of the compound comes from the observation that we
were never able to demonstrate capsular growth induction in
experiments where fungal and amoeba cells were separated by
diffusible membranes. Direct evidence for the instability of the
capsule-inducing compound comes from the observation that
extracts rapidly lost their activity when stored at room tempera-
ture. The instability of the activity suggests an explanation for our
difficulties in the attempts to further purify and identify the active
compound(s) responsible for capsule enlargement. In retrospect,
the putative identification of the active compound as a
phospholipid suggests an explanation for its instability since these
compounds are rapidly degraded by molecular oxygen and our
protocols did not involve working in oxygen-free conditions.
However, it is also possible that the inability to demonstrate
capsular enlargement in assays with diffusible membranes
indicates strong concentration dependence such that the effect is
lost with dilution.
Our second approach to molecular identification was to
consider compounds that may be present in the polar extract, to
obtain them in pure form, and to test them individually, and
sometimes in combination, for their effects on capsule growth.
Using this approach, we found that phospholipids, in particular,
phosphatidylcholine (PC) and lysophosphatidylcholine (LC) and
two glycerophosphodiesters, GPC and GPE, that are components
of the polar head of phospholipids, were able to reproduce the C.
neoformans capsule enlargement. Additionally, GPC and GPE were
able to overcome the inability of the phospholipase B mutant to
enlarge its capsule in response to the amoeba extract. This was in
contrast to intact PC, supporting the necessity of PLB activity to
generate these small compounds that trigger phospholipid-
mediated capsule enlargement. The fact that GPC and GPE are
regularly found in brain and other host tissues [36], also suggests
that they could act as possible triggers for the capsule increase
observed with C. neoformans in the host environment [37].
Although the mechanism by which phospholipids trigger
capsule enlargement was not elucidated as part of this study, our
working hypothesis is that certain phospholipids can trigger
signaling cascades in C. neoformans that in term promote capsule
synthesis. In this regard, we note that members of the human
oxysterol binding protein (OSBP) family can bind phospholipids
[38] and it is conceivable that in C. neoformans this highly conserved
family, or another signaling set of proteins, has been specialized to
bind phospholipids.
The finding that phospholipids triggered capsular enlargement
led to a conundrum; neither the lower phase extract from
amoebae nor from macrophages mediated this effect, however
phospholipids would have been abundant in the organic layer.
Our hypothesis is that the complex lipid solution in the lower
phase includes both stimulators and inhibitors of capsule
enlargement. In this regard, we note that this fraction would also
include all the sterols and this class of compounds can trigger
signal transduction by the OSBP-related protein system [39]. In
yeast, stimulation of these proteins inhibits golgi vesicular
production [40]. An analogous effect in C. neoformans could shut
down capsule production since the polysaccharide is synthesized in
golgi-derived vesicles [41]. In this regard we note that in the dose
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peaked at 10 mM and declined at higher concentrations consistent
with an inhibitory effect. Alternatively, there could be a possible
nutritional explanation. Capsule size is known to be negatively
regulated by nutrient-rich media and high glucose concentrations
(reviewed in [3]). Consequently, it is possible that the lipid-rich
environment of the lower phase is perceived by the fungus as
nutrient-rich, leading to inhibition of capsular enlargement. Given
that capsular enlargement has been associated with poor nutrient
preparations and stationary phase growth conditions, combined
with the recent observation that giant cell formation in C.
neoformans follows cell cycle progression without fission [6,7], we
decided to evaluate the effects of our lipid preparations on cell
growth but found no effect. Similarly, lipid-induced capsule
growth was observed at all tested temperatures with the exception
of extremely low, non-physiological temperatures. The occurrence
of capsule enlargement at temperatures ranging from ambient to
mammalian, suggests that this phenomenon can occur both in
environmental niches and during mammalian infection.
We also observed that co-incubations with extracts or cells of A.
castellanii and macrophages for extended periods induced the
formation of very large cells. Although these cells did not achieve
the full dimensions of giant cells described in vivo, they
approximated that size and represented a tremendous increase
in both cell and capsule sizes. Given that detailed studies of giant
cells are likely to require the ability to induce them in vitro, the
finding that these extracts promoted their formation is an
important development for future progress in understanding their
cell biology. This type of C. neoformans cells displayed a double-
layered capsule, consisting of a denser region close to the cell body,
and an outer layer, which permitted a higher penetration of India
ink particles. Immunofluorescence studies revealed that binding of
mAbs to the capsule of C. neoformans cells following incubation with
amoeba or extracts was more intense, indicating the presence of
more reactive polysaccharides surrounding the yeast. An increase
in the cell body was observed after eight days of incubation with
amoeba or macrophage cells and extracts when compared to PBS
alone, along with a concurrent decrease in capsular volume, but
no alteration in the whole cell volume. This suggests that in the
conditions of starvation that accompany the late stationary phase,
C. neoformans might be reusing the capsular polysaccharides as an
energy source.
In summary, we describe a new trigger for cryptococcal capsule
enlargement that is present in the polar lipid fractions derived
from amoebae, macrophages, and mammalian serum. We propose
a model for C. neoformans capsule enlargement resulting from
interactions with amoebae or macrophages, whereby C. neoformans
induces release of phospholipids from the phagocytic cell
membrane after action of PLB possibly facilitated by C. neoformans
proteases [42]. Those phospholipids are then cleaved by PLB
releasing their polar heads that are in turn sensed by C. neoformans
cells, triggering capsule enlargement and the formation of giant
cells (Figure 9). Since capsule enlargement reduces the phagocytic
efficacy of both amoeba and macrophages [4,21], we propose that
Figure 9. Schematic drawing summarizing the observations made in this study. C. neoformans is proposed to release enzymes that
damage the cell membrane of amoebae and macrophages thus releasing phospholipids, possibly in combination with proteins. Those phospholipids
are then cleaved by PLB, releasing their polar heads that are in turn sensed by C. neoformans cells, triggering capsule enlargement and the formation
of giant cells.
doi:10.1371/journal.ppat.1002047.g009
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potential danger. The observations with phospholipase B-sufficient
and -deficient cells, suggest that fungal enzymes are used to
damage amoeba cell membranes and release lipid components
that subsequently trigger capsule growth. According to this view,
the fungus would sense the lipid components and/or cleavage
products (GPC or GPE) as signals of potential danger in the form
of predatory phagocytic cells in their immediate vicinity. In this
hypothesis, phospholipids join other known triggers of capsule
growth such as Fe deprivation, CO2, and pH as stress signals to
which the fungus responds by capsular enlargement. To our
knowledge, these are the first host-derived compounds identified to
promote capsular and cellular enlargement. Our observations
provide yet another striking parallel between the response of C.
neoformans to amoebae and macrophages. Such similarities,
combined with the observations that virulence can be enhanced
by passage in amoeboid cells [1], have been used to argue that the
capacity for virulence in C. neoformans and other soil-dwelling
organisms with no requirement for animal hosts is a consequence
of selective pressures in soils from the presence of protozoa.
Recently, the same argument has been put forward to explain the
virulence of certain fungi for insects [14]. The parallel responses of
C. neoformans to macrophages and amoebae provide additional
support for the view that cryptococcal virulence is a result of
selection of certain traits by environmental pressures that also
enhance survival in animal hosts.
Materials and Methods
Organisms and culture conditions
A. castellanii strain 30234 and C. neoformans strain 24067 were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA). The amoebae were cultured in peptone-yeast
extract-glucose broth, PYG (ATCC medium 712, containing
10 mM glucose), in tissue culture flasks at 28uC. A. castellanii cells
were used when confluent on the bottom of the flask and were
passaged every 5-7days, as described [43]. The C. neoformans strains
24067 (serotype D) and H99 (serotype A) were grown from frozen
stocks and maintained in Sabouraud dextrose broth (SDB, Difco,
Lawrence, KS) or minimal medium (MM, 15 mM glucose,
10 mM MgSO4, 29.4 mM KH2PO4, 13 mM glycine, and 3.0
ı `M thiamine). C. neoformans strains H99, plb1, and plb1
REC1 [24]
were obtained from Drs. Gary Cox and John Perfect (Durham,
NC). C. neoformans strains H99, Disc1, and Disc1
REC strains [44]
were obtained from Dr. Maurizio Del Poeta (Charleston, SC).
Effect of amoeba co-incubation on C. neoformans capsule
size
After growing C. neoformans as described above, the cells were
washed 3 times in phosphate buffered saline (PBS) and 1610
6
yeast cells were suspended in either PBS or MM and placed in 96-,
24-, or 6-well plates. Cryptococcal cells were incubated with
1610
6 of either: live or dead A. castellanii or J774.14 macrophage-
like cells. Alternatively, C. neoformans was incubated with 9.2 mm
polystyrene beads. Incubations were done overnight, for 24 h or
48 h at 28uC. Dead amoebae were obtained by boiling the
organism for 5 minutes. Lysing of amoeba cells was accomplished
by forcefully pulling and pushing the cell suspension through 26.5
gauge syringe needles 15-20 times. Additionally, C. neoformans cells
were incubated in medium conditioned by prior growth of A.
castellanii or cell-free supernatant from a previous overnight co-
incubation experiment. To evaluate the effects of temperature in
the interaction, plates with C. neoformans strain H99 and A. castellanii
were also incubated overnight at 4uC, room temperature, 28uC,
and 37uC.
Capsule measurement
The volume of the capsule both before and after exposure to the
various conditions was measured using India ink suspensions, as
previously described [8]. After overnight incubation for each
condition tested, C. neoformans cells were washed from the wells,
spun down, and in some cases stained with Uvitex 2B
(Polysciences, Inc.), and then all aliquots were spotted on
microscope slides, mixed with a drop of India ink, and examined
using an Olympus AX70 microscope at a magnification of 40X
(Center Valley, PA). Cells suspended in India ink were
photographed with a QImaging Retiga 1300 digital camera using
the QCapture Suite V2.46 software (QImaging, Burnaby, British
Columbia, Canada). Alternatively, C. neoformans cells were
observed in an Axiovert 200 M inverted microscope using a
40X objective (Carl Zeiss Micro Imaging, Thornwood, NY) and
photographed using a Hamamatsu ORCA ERJ camera (Hama-
matsu Photonics, Hamamatsu City, Japan). The volume of the C.
neoformans capsule was measured using Adobe Photoshop 7.0 for
Windows (San Jose, CA.), or AxioVision software (Carl Zeiss
Micro Imaging, Thornwood, NY). The diameter of the whole cell
(Dwc) and the cell body (Dcb) were each measured and the capsule
width was defined as the difference between Dwc and Dcb.
diameters. The volume of the capsule was calculated using the
equation for the volume of a sphere, 4/3 P(D/2)
3, such that the
capsule volume (Vc) was the difference between the whole cell
volume (Vwc) and the volume of the cell body (Vcb). For each
condition, we averaged the capsule volume for a minimum of 50
C. neoformans cells.
Investigation into requirements for cellular contact
To determine whether cell contact was needed for C. neoformans
to respond with capsular enlargement, experiments were carried
out where fungal and amoeba cells were separated by means of
filter inserts. C. neoformans cells were placed in 24 well plates and
separated from A. castellanii by the presence of a cell culture insert
with a 0.4 ı `m pore size (BD Falcon, Franklin Lakes, NJ). Prior to
co-incubation, C. neoformans cells were suspended in PBS and
placed below the inserts. Above the inserts, either A. castellanii with
C. neoformans, A. castellanii alone, or PBS was then placed. The
plates were incubated for either 24 or 48 h at 28uC. A third group
was incubated for 24 h with PBS below the filter prior to the
addition of the C. neoformans and then C. neoformans was added for
an additional 24 h of incubation. All organisms were suspended at
a density of 1610
6/mL and at an initial 1:1 ratio of fungal to
amoeba cells.
Lipid extraction
Cells from confluent A. castellanii cultures were collected by
centrifugation at 320 x g for 10 min. J774.14 macrophage-like
cells were also collected by centrifugation after growth to
confluence; however, they were spun at 320 x g for 7 min. Cell
pellets were washed three times with PBS. Resuspended pellets
(10
8 cells in 10 mL) of A. castellanii, macrophages, or aliquots of
Fetal Calf Serum (FCS) were each incubated with a mixture of
chloroform and methanol (2:1 v:v) for 2-3 h on a bench top rocker
at room temperature. The samples were then centrifuged for
10 min at 1100 x g for phase partitioning and the three phases
obtained (upper, interface, and lower) were collected and dried
overnight in a vacuum centrifuge (Eppendorf, Hauppauge, NY,
USA). Interface and upper phase lipid fractions were resuspended
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sulfoxide (DMSO).
Capsular enlargement assay upon fractionation
After resuspension, the amoeba and macrophage extracts were
tested in capsular enlargement activity assays with C. neoformans
strains 24067 and H99 and serum extracts were added as well for
the tests with C. neoformans strains H99, plb1, and plb1
REC1. For
each activity assay, C. neoformans cells were washed, counted, and
resuspended at 1610
6 cells/mL in PBS. A 1 mL volume of the cell
suspension was added to each well of a 6-well plate. An additional
1 mL of PBS, and 1610
6 of A. castellanii cells, were always added to
the first and second wells, respectively. In general, 1 mL of a
solution of the fraction to be tested was added to each of the
subsequent wells, with the concentration determined by the
particular experiment. The plates were incubated at 28uC
overnight, 24 or 48 h and capsule volume was measured using
India ink staining (described above).
Requirement of phospholipase activity for capsule
enlargement
In addition to strains 24067 and H99, experiments were
performed with C. neoformans strains H99, plb1, and plb1
REC1 to
determine the effect of phospholipase B deficiency on the ability to
respond to co-incubation with amoeba extracts [24]. Strains H99,
Disc1, and Disc1
REC were tested to determine the effect of
phospholipase C deficiency on the ability to show activity [44].
Stability of the capsule-inducing amoeba polar extract
The upper phase of the amoeba extract was suspended in PBS
and tested for its ability to induce capsule enlargement as
described above. A series of aliquots were left at room temperature
and one was tested each day for the ability to elicit capsule
enlargement. This experiment was conducted until no effect on
capsule enlargement was observed.
Amoeba polar extract activity following thermal and
enzymatic treatments
In order to evaluate the chemical characteristics of the active
molecule(s) in the polar extract, the extracts were submitted to
various treatments. Treatments included: (1) heat for 1 h at 65uC,
(2) Proteinase K treatment [100 mg/mL in 50 mM Tris-HCl
(pH 8.0) and 1.0 mM CaCl2] for 1 h at 37uC followed by enzyme
inactivation at 70uC for 30 min, or (3) treatment with 1 U of
Aspergillus niger b-glucanase (Sigma Aldrich). The capsule volumes
of the C. neoformans cells after overnight incubation with the various
treated extracts were then compared to cells incubated in PBS
alone or incubated with untreated extracts.
Thin layer chromatography
To investigate what was released after the enzymatic treatments
listed above, thin layer chromatography (TLC) was performed. A
similar volume of all the fractions to be tested was dried,
resuspended in chloroform, and 25 mL were spotted onto the
membrane. A general separation of phospholipids based on head
group polarity was done using a mobile phase composed of
chloroform:methanol:water (65:25:4). Four of the main phospho-
lipids known to be present in A. castellanii cells, L-a-Phosphati-
dylethanolamine (unsaturated, from Glycine max), L-a-Phospha-
tidylcholine (unsaturated, from Glycine max), L-a-
Phosphatidylinositol (unsaturated, from Glycine max), and 1,2-
Diacyl-sn-glycero-3-phospho-L-serine (unsaturated, from bovine
brain) were purchased from Sigma-Aldrich (St. Louis, MO) [45]
and used as standards. TLC plates were dried and stained in an
iodine vapor chamber until the spots formed.
Fractionated extracts tested upon enzymatic treatment
Upon treatment with Proteinase K as described above, samples
were submitted to a second round of fractionation with a mixture
of chloroform and methanol (2:1 v:v) for 2–3 h as described above.
Upper and lower phases were then tested for capsular enlargement
activity as described above.
Purified molecules tested for capsular enlargement
activity
Phospholipids known to be present in A. castellanii were
purchased from Sigma-Aldrich (St. Louis, MO) [45]. 3-sn-
Phosphatidic acid sodium salt from egg yolk lecithin (PA), L-a-
Phosphatidylcholine from egg yolk (PC), L-a-Phosphatidyletha-
nolamine from egg yolk (PE), L-a-Phosphatidyl-DL-glycerol
sodium salt from egg yolk lecithin (PG), L-a-Phosphatidylinositol
from Glycine max (PG), 1,2-Diacyl-sn-glycero-3-phospho-L-serine
from bovine brain (PS), and L-a-Lysophosphatidylcholine from
bovine brain (LC), were each tested with C. neoformans for their
ability to induce capsular enlargement. Arachidonic Acid,
Epoxyeicosatrienoic Acid, Thromboxane B2, Prostaglandin E2,
Prostaglandin I2, Leukotriene B4, and Leukotriene C4 were also
purchased from Sigma-Aldrich (St. Louis, MO). The powders
were resuspended in PBS, MM, or ethanol, serially diluted, and
tested in the activity assay with C. neoformans strains H99 and
24067. Purified glycerophospholethanolamine (GPE) and glycer-
ophosphocholine (GPC) were purchased from Avanti Polar Lipids
(Alabaster, Alabama). These two substances were tested in activity
assays with C. neoformans strains 24067, H99, plb1, and plb1
REC1.
For GPC and GPE, we tested concentrations ranging from
0.1 mM to 1 mM and found that 10 mM was the lowest
concentration where we observed activity. The activity did not
increase at higher concentrations. For PC, we chose a 5 mM
concentration based previous studies [26]. Additionally, we carried
out a dose response study and found that for PC the effect was
higher at concentrations equal to or higher than 1 mM. As the
effects of GPC, GPE, and PC were stronger in MM in comparison
to PBS, most of the tests were done in this condition.
Exopolysaccharide and capsular polysaccharide
production under treatment with amoeba extract
C. neoformans cells were incubated with amoeba extracts in either
PBS or MM and the resulting pool of polysaccharide was
evaluated by ELISA. Exopolysaccharide and capsular polysac-
charide were measured by an inhibition ELISA on reaction plates
to which 10 mg/well of glucuronoxylomannan (GXM) [46] was
affixed overnight, followed by blocking with 1% (w/v) bovine
serum albumin diluted in PBS (blocking buffer), and then
subjected to mAb binding [47]. A second blank ELISA plate
(inhibition plate) was blocked for 1 h at 37uC and a solution of
2 mg/mL of mAb 18B7 [48] was incubated with serial dilutions of
GXM (concentrations of 10 mg/mL to 0.06 ng/mL) or capsular
and exopolysaccharide samples at 37uC for 1 h. Contents of the
wells were transferred to blocked reaction plates with adherent
GXM as antigens. After incubation at 37uC for 1 h, the plates
were washed and anti-mouse IgG conjugated with alkaline
phosphatase (1:1000 in blocking buffer) was added to the wells
for 1 h at 37uC. The plates were again washed, incubated with a p-
nitrophenyl phosphate substrate solution and read at 405 nm. The
concentration of GXM in the samples was calculated extrapolating
from the GXM standard curve.
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Aliquots of C. neoformans suspensions following incubation with
amoeba extracts were washed with PBS, centrifuged, and
suspended in a 50 mg/mL solution of 18B7 mAb in a 5% Bovine
serum albumin solution in PBS. Tubes were incubated for 1 h at
37uC while shaking and then washed three times with PBS. The
pellets were suspended in 100 ml of a 1:100 dilution of FITC-
conjugated goat anti-mouse IgG1 (Southern Biotechnology) in
blocking solution. Tubes were again incubated for 1 h at 37uC and
washed with PBS. Pellets were then suspended in mounting
medium (Biomeda Corp, Foster City, CA) and spotted onto a
microscopy slide. Slides were examined with an Olympus AX70
fluorescence microscope using a 495 nm filter, at a magnification
of 40X. Alternatively, 10
7 C. neoformans cells were stained for 1 h
with 10 mg/mL DTAF-labeled 18B7 mAb and 0.01% Uvitex 2B.
After washing, cells were suspended in Prolong gold anti-fade
mounting medium (Invitrogen, Carlsbad, CA) and imaged using a
63x 1.4 objective. Z-stacks were collected and deconvolved using a
constrained iterative algorithm from AxioVision software (Carl
Zeiss Micro Imaging, Thornwood, NY).
Growth Curves
A Bioscreen-C Automated Growth Curve Analysis System
(Growth Curves USA, Piscataway, NJ) was used to measure the
growth of C. neoformans strain 24067 in the presence of the A.
castellanii polar extract. The fungal cells were incubated either
alone in PBS or in PBS and 1 mLo r1 0mL of polar extract and
compared with the cells incubated in SDB alone or in SDB and
1 mLo ro f1 0mL polar extract.
Mass spectrometry of polar extracts
Polar extracts and polar extract samples after treatment with
proteinase K and lipid re-extraction by the FoIch method were
submitted to mass spectrometry analysis by the Kansas Lipidomics
Research Center (Manhattan, KS).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 (La
Jolla, CA). The Shapiro-Wilk test was used to verify normal
distribution of the measurements. To determine significance, One-
way ANOVA tests were used, followed by either correction with
the Bonferroni test for multiple pairwise comparisons for normally
distributed values or the Kruskal-Wallis analysis for measurements
that were not normally distributed. P values of less than 0.05 were
considered significant.
Supporting Information
Figure S1 A. Dose-response effects of phosphatidylcholine (PC)
on capsule enlargement of C. neoformans. B. Effects of different
phospholipid classes on capsule enlargement of C. neoformans. C.
neoformans cells were incubated for 48 h in minimal media (MM)
alone or MM containing 1 mM of one of the following lipids:
phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidyl-
ethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinosi-
tol (PI), phosphatidylserine (PS), or lysophosphatidylcholine (LC).
All the compounds, with the exception of PG and PS, produced
significant enlargement of the C. neoformans capsule volume. PC
and LC also produced significant enlargement of C. neoformans cell
body volume. Conversely, PS produced significantly smaller cells.
(*) denote p,0.05 relative to cells in minimal media alone.
(TIF)
Figure S2 Dose response effects of GPC, GPE on capsule
enlargement of C. neoformans. C. neoformans cells were incubated for
48 h in minimal media (MM) alone or MM containing different
concentrations of GPC and GPE. (*) denotes p,0.05 relative to
cells in minimal media alone.
(TIF)
Figure S3 Effects of PLB inhibitors on C. neoformans capsule
enlargement induced by phosphatidylcholine (PC). C. neoformans
24067 cells were incubated for 48 h in minimal media (MM) alone
or in MM containing 5 mM PC alone or 5 mM PC with
compound AX, compound O, or palmitoyl carnitine (PAC).
Compound AX, which targets mainly secreted PLB activity, did
not affect the capsule enlargement, while compounds O and PAC
abolished the effects of PC. (*) denote p,0.05 relative to cells in
minimal media alone.
(TIF)
Table S1 List of compounds that failed to elicit capsular
enlargement of Cryptococcus neoformans cells suspended in PBS.
(TIF)
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